Tyra Biosciences (NASDAQ:TYRA) Issues Earnings Results, Beats Estimates By $0.05 EPS

Tyra Biosciences (NASDAQ:TYRA) announced its quarterly earnings results on Thursday. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05, Zacks reports.

Tyra Biosciences Trading Up 2.6 %

Shares of Tyra Biosciences stock traded up $0.25 on Friday, reaching $9.91. 57,068 shares of the stock were exchanged, compared to its average volume of 282,164. The firm has a market capitalization of $501.43 million, a PE ratio of -6.15 and a beta of 1.09. Tyra Biosciences has a 1-year low of $9.48 and a 1-year high of $29.60. The business has a fifty day moving average price of $12.59 and a two-hundred day moving average price of $16.45.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 21,998 shares of company stock worth $344,818 over the last 90 days. Company insiders own 15.40% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.